ImpACTIVE Holdings Ltd. is pleased to announce it’s intentions to apply for Health Canada licensing as a Cannabis Health Product and list on the Canadian Recreational Cannabis Markets pursuant to a Letter of Intent and strategic partnership with Creso Pharma Ltd. (previously announced March 9th, 2021).
Both parties expect to introduce the new suite of products that include both a THC-CBD hybrid solution and the original line of CBD-only solution to new and existing markets, including the Canadian and North American recreational sports market. ImpACTIVE will work alongside Creso Pharma’s existing management teams in Canada and the US to target licenced CBD retailers, as well as large department and sporting chains to increase sales.
As part of the LOI, Creso Pharma is also continuing to pursue purchase orders for ImpACTIVE products through its key wholesalers in Switzerland and 2,100 distribution points through pharmacy networks, drugstores and specialised retailers.
ImpACTIVE is a Canadian company, founded by current and former high-profile athletes who have struggled with injury and wanted to provide an alternative treatment route to the athletic community. ImpACTIVE has developed a range of CBD based products, designed to reduce muscle and joint inflammation without the use of heavy narcotics or prescription pharmaceuticals, and its products are promoted by several well-known brand ambassadors.